MASSTRPLAN – MASS spectrometry TRaining network for Protein Lipid adduct ANalysis

MASSTRPLAN is a multidisciplinary network of 6 academic beneficiaries, 2 hospital beneficiaries and 2 commercial beneficiaries, collaborating with 15 partners (technology, pharmaceuticals & life science-related industries, hospital & academic teams, and learned societies). Its focus is on “Lipoxidation”, which means the modification of proteins by reactive lipid oxidation products. Oxidative modifications and lipoxidation of proteins occur in inflammatory diseases, leading to cellular dysfunction and disease pathology; the development of improved mass spectrometry approaches will enable them to be analysed more efficiently. MASSTRPLAN will train 14 Early Stage Researchers (ESRs) in translational science centred on advanced analytical techniques to detect oxidized phospholipids & proteins in biological & clinical samples, evaluate their biochemical roles, and develop new diagnostic tools for commercialization.

MASSTRPLAN is funded by the European Commission’s REA with the H2020 MSCA with a total budget of €3.5 million. The project started on the 1st October 2015 and will run for 4 years.

MASSTRPLAN has both research objectives and training objectives.

The research objectives are to develop new and quantitative mass spectrometry methodologies for analysis of lipid / protein oxidation and lipoxidation products and apply them to study lipoxidation in biological and clinical samples, in order to understand their biological effects and role in inflammatory diseases, and develop new diagnostic tools.

The training objective is to equip a new generation of researchers with broad mass spectrometry skills suitable to tackling the study of chronic inflammatory mechanisms at a molecular and cellular level, plus translational skills in bioinformatics, clinical methods and product development to yield healthcare benefits in major disease areas.


  • MASSTRPLAN will generate a cohort of early stage researchers with advanced instrument training in MS and analytical technologies to detect inflammatory damage, filling the current gap in this training area.
  • MASSTRPLAN will advance the MS methodology and detection of oxidative modifications to lipids and proteins, leading to improved understanding of inflammatory diseases including diabetes, atherosclerosis and cardiovascular disease, autoimmune diseases and cancer.
  • MASSTRPLAN will develop new commercializable diagnostic tools for detecting lipoxidation in biological and clinical samples.
  • MASSTRPLAN will raise awareness of the importance of advanced mass spectrometry and “beyond-omics” approaches to study and diagnose specific inflammatory pathologies.

Masstrplan Team